IPAR · Interparfums, Inc. · Stock research

Current Thesis

Interparfums has re-rated roughly +38.6% YTD and +26.2% in the past month (to ~$119.28 on 2026-07-10, with a 2026-07-07 range of $120.53–$124.33) on a rotation-into-quality-defensives bid. The tension: this is happening in a year management guides EPS down. FY2026 guidance, reaffirmed at the Q1 print (reported 2026-04-21, call 2026-05-06), is net sales $1.48B (+1%) and EPS $4.85 a ~5% decline versus 2025 as capital gets redirected into emerging labels (Off-White, Longchamp) ahead of a planned 2027 rollout. So the price leg is multiple expansion, not earnings growth. The narrative is late-stage: mainstream coverage is already flagging it, and sell-side price targets sit below spot. Best read as a maturing rotation trade rather than an accelerating fundamental story.

Bullish and bearish views on Interparfums, Inc.

The model's bull view on Interparfums, Inc. (IPAR), in brief: Lacoste posted FY sales of $108M in its second year under management (+28%), beating the $100M plan the anchor license is compounding, not fading. The bear view: The core problem: FY2026 EPS is guided to $4.85, a ~5% decline, on sales +1%. Both cases follow in full.

Bull Case

• Lacoste posted FY sales of $108M in its second year under management (+28%), beating the $100M plan the anchor license is compounding, not fading.
• License pipeline is stacking: 20-year worldwide deals signed with Nautica and David Beckham, and Guess extended through 2048 building the 2027 reacceleration case.
• Q1 2026 (2026-04-21): record net sales $344.9M (+2% YoY), EPS $1.35 (+2%, ~14% above consensus), gross margin 65.1% vs 63.7% prior margin expansion despite tariff noise.
• Balance sheet funds the investment year cleanly: $237M cash and short-term investments, $692M working capital (Q1 2026).
• Quality-defensive factor bid intact: above the 200-DMA, the affordable-luxury "lipstick effect" is the rotation magnet in a jittery consumer tape.
• Dividend $0.80/qtr (paid 2026-06-30), ~2.6% yield a holder's carry while the 2027 story develops.

Bear Case

• The core problem: FY2026 EPS is guided to $4.85, a ~5% decline, on sales +1%. A +38% price move on falling earnings is entirely multiple re-rating.
• Sell-side is both behind and below the tape: average PT $106 (MarketBeat, 2026-07-10), high target $123 ≈ spot, low $85; 3 of 8 analysts at Hold. TD Cowen initiated Buy on 2026-06-01 but at only $110.
• Mainstream coverage is flagging it: "Top 3 Defensive Stocks That May Fall Off A Cliff This Quarter" (2026-07-10) CNBC-style framing is a late-cycle signal.
• Stretched: ~$119–124 sits roughly 25% above the 90-DMA ($97) and 45-DMA ($95); a mean-reversion gap exists with no fresh fundamental catalyst to defend it.
• Management flagged tariff and margin pressure through 2026 from portfolio streamlining and emerging-label investment near-term earnings drag is a guide feature, not a surprise.

Setup & Price Structure

• Last ~$119.28 (2026-07-10); intraday $120.53–$124.33 on 2026-07-07; $115.67 on 2026-07-01 (+3.4% day). 52-week range $77.21–$139.94.
• Breakout leg: advanced off the $95–97 MA cluster through a $110–115 shelf into early July, pressing toward the 52-week high.
• Momentum is real but extended above the 200-DMA and all shorter averages, RSI elevated after a ~26% month.
• Overhead: 52-week high $139.94 and GF Value $137.80. Support: the $110–112 breakout shelf, then the $95–97 MA cluster on a deeper unwind.

Catalyst Calendar (next 30 days)

• ~2026-08-06 (est.): Q2 2026 results and conference call. Historically early August (Q2 2025 call ~2026-08-07 analog). This is the binary for the re-rating a reaffirm-only print on -5% EPS guidance gives flow buyers little to hold; a guide-raise pulling 2027 forward is what the multiple needs.
• Q2 dividend declaration expected alongside earnings (prior $0.80/qtr).
• No FDA/binary company events; the swing factor is whether the consumer-defensive rotation stays bid into August.

What Would Change Our Mind

• A weekly close below $110 loses the June–July breakout shelf and signals the rotation bid unwinding toward the $95–97 mean.
• A Q2 print (~2026-08-06) that trims the $1.48B / $4.85 guide, or the consumer-defensive rotation theme flipping to saturated as the trade rolls over.

Correlation Notes

• Moves with the beauty and affordable-luxury complex (EL, COTY) and the broad consumer-discretionary rotation; a quality-defensive factor bid drives it more than any fundamental beat.
• Fragrance remains the resilient corner of soft luxury; the license model is lower-beta than direct-brand luxury (LVMH, EL) but re-rates on the same rotation flows.
• FX-sensitive majority of production and sales are France-based, so USD/EUR and tariff headlines feed directly into the margin narrative.